![Medicinal Cannabis Draws Eyes as Oil Slides and Bond Yields Climb [FTSE AIM UK 50 INDEX]](https://cedclinic.com/wp-content/uploads/2026/06/ced-unsplash-ke6jYtwXDKA-1-150x150.jpg "Medicinal Cannabis Draws Eyes as Oil Slides and Bond Yields Climb [FTSE AIM UK 50 INDEX] 25")
Policy Watch: 10 Regulatory Updates — March 20, 2026
The DEA rescheduled marijuana from Schedule I to Schedule III, recognizing its medical utility. This regulatory update impacts prescribing restrictions for healthcare providers. The dea rescheduled marijuana change is a significant development in…
Policy Watch: 17 Regulatory Updates — March 17, 2026
This update covers cannabis medicine regulatory updates relevant to clinicians and patients. Key topics include controlled substances scheduling and Medicare payment policies. These cannabis medicine regulatory updates impact clinical practice and…
Policy Watch: 25 Regulatory Updates — March 12, 2026
The March 12, 2026 update covers DEA scheduling synthetic drugs and related regulatory affairs. This includes synthetic opioids and marijuana rescheduling proposals. Clinicians should note implications for controlled substances management.
Policy Watch: 20 Regulatory Updates — March 10, 2026
This update covers DEA scheduling synthetic opioids and regulatory changes relevant to cannabis clinicians. The rescheduling of marijuana signals potential federal recognition of cannabis medical utility. These regulatory updates impact clinical practice…